Amgen Inc. $AMGN Stake Boosted by Integrity Alliance LLC.

Key Points

• Integrity Alliance LLC. boosted its Amgen stake by 57.5% in the fourth quarter, buying 3,932 more shares and bringing its total to 10,765 shares valued at about $3.52 million.
• Amgen reported better-than-expected Q1 earnings, with EPS of $5.15 on revenue of $8.62 billion, both topping analyst estimates, while revenue rose 5.8% year over year.
• The company also declared a quarterly dividend of $2.52 per share, implying a 3.0% annualized yield, even as analysts maintain a consensus rating of “Hold” with an average target price of $355.19.

Integrity Alliance LLC. increased its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 57.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,765 shares of the medical research company's stock after purchasing an additional 3,932 shares during the quarter. Integrity Alliance LLC.'s holdings in Amgen were worth $3,524,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. High Note Wealth LLC increased its stake in Amgen by 5.8% in the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company's stock worth $166,000 after purchasing an additional 28 shares in the last quarter. West Family Investments Inc. increased its stake in Amgen by 1.1% in the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company's stock worth $779,000 after purchasing an additional 30 shares in the last quarter. Viawealth LLC grew its stake in Amgen by 0.4% during the 3rd quarter. Viawealth LLC now owns 7,168 shares of the medical research company's stock valued at $2,023,000 after acquiring an additional 30 shares in the last quarter. LOM Asset Management Ltd grew its stake in Amgen by 1.2% during the 3rd quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company's stock valued at $721,000 after acquiring an additional 30 shares in the last quarter. Finally, Smith Salley Wealth Management grew its stake in Amgen by 0.3% during the 4th quarter. Smith Salley Wealth Management now owns 10,786 shares of the medical research company's stock valued at $3,530,000 after acquiring an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the business's stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.85% of the company's stock.

Amgen Stock Up 0.0%

Shares of Amgen stock opened at $336.06 on Thursday. The firm has a market cap of $181.37 billion, a price-to-earnings ratio of 23.39, a P/E/G ratio of 3.37 and a beta of 0.44. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. Amgen Inc. has a 52-week low of $267.83 and a 52-week high of $391.29. The stock has a 50-day simple moving average of $343.32 and a 200-day simple moving average of $345.27.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm's revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the company earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities research analysts expect that Amgen Inc. will post 22.37 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 3.0%. The ex-dividend date is Friday, May 15th. Amgen's payout ratio is 70.15%.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Wells Fargo & Company lifted their target price on Amgen from $375.00 to $390.00 and gave the company an "equal weight" rating in a research note on Thursday, March 19th. TD Cowen reaffirmed a "buy" rating on shares of Amgen in a research note on Wednesday, February 4th. Guggenheim lowered their target price on Amgen from $351.00 to $340.00 and set a "neutral" rating on the stock in a research note on Monday, May 4th. Barclays assumed coverage on Amgen in a research note on Friday, February 20th. They set an "equal weight" rating and a $350.00 target price on the stock. Finally, Citigroup lifted their price target on Amgen from $315.00 to $345.00 and gave the company a "neutral" rating in a report on Wednesday, February 4th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $355.19.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.